messag signific beat driven robust trikafta
launch compani accordingli rais guidanc may still conserv
view covid disrupt rel minim commerci given earli
prescript advanc purchas quarter though pipelin
studi paus time around initi patient enrol fsg trial
tbd program move clinic later year/earli next reiter buy
pt increas vs previous
compani report factset data guggenheim secur llc note million except per share data
new pt vs previou driven adjust cf
market share reflect quarterli perform far year management updat
guidanc well updat reflect report
page analyst certif import disclosur
compani report guggenheim secur llc research
page analyst certif import disclosur
base dcf valuat arriv pt vs previou pt forecast probability-weight revenu expens
assum discount rate termin growth rate po gene therapi po aatd
fsg program po program increas pt driven adjust cf market share reflect
quarterli perform far year management updat guidanc well updat reflect report
suscept risk appli entir biotech industri includ develop regulatori commerci
manufactur financ ip risk specif includ
clinic risk delay clinic trial initi unexpect safeti issu efficaci lower expect
regulatori risk clinic trial ultim success possibl vrtx medicin approv global regulatori
agenc given novelti technolog agenc may requir addit long-term data could delay potenti
ip risk crispr landscap rapidli evolv guarante access new develop
technolog emerg space
competitor risk technolog wide follow public media possibl news
technolog unrel /crsp could lead downsid share
page analyst certif import disclosur
mm except per share data
factset consensu
total incom expens net
incom tax
loss attribut non-controlling interest
net incom attribut
non-gaap net incom attribut
factset consensu
gaap cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
